Extension Study With rVIII‐SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A
RVIII-SingleChain demonstrated a satisfactory benefit:risk profile in PUPs, with a high treatment success rate and a low AsBR during prophylaxis, and was effective at eradicating inhibitors.
Authors
- Amy Suen
- Blanca Salazar (ORCID: https://orcid.org/0000-0001-5298-6009)
- Maria Elisa Mancuso (ORCID: https://orcid.org/0000-0002-7113-4028)
- Kathelijn Fischer (ORCID: https://orcid.org/0000-0001-7126-6613)
- Claudia Djambas Khayat (ORCID: https://orcid.org/0000-0002-5584-5049)
- Faraizah Abdul Karim (ORCID: https://orcid.org/0000-0001-6954-2906)
- Thomas Chung
- Christoph Königs (ORCID: https://orcid.org/0000-0003-4597-2439)
- Shawn M. Jobe (ORCID: https://orcid.org/0000-0001-7878-6101)
- Johnny Ndoni Mahlangu (ORCID: https://orcid.org/0000-0001-5781-7669)
- Manuela Carvalho (ORCID: https://orcid.org/0000-0002-0973-6677)
- Brahm Goldstein
- Samantha Lucas
- Wilfried Seifert
Institutions
- Goethe University Frankfurt (DE)
- Humanitas University (IT)
- Saint Joseph University (LB)
- University of the Witwatersrand (ZA)
- Hospital de São João (PT)
- University Medical Center Utrecht (NL)
- Behringwerke (Germany) (DE)
- CSL (United States) (US)
- Versiti Blood Center of Wisconsin (US)
- University Hospital Frankfurt (DE)
- Hôtel-Dieu de France (LB)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Haemophilia
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1111/hae.15151
- Citations
- 1
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- CSL Behring